Dr. Singal on the FDA Approval of Cabozantinib in HCC
January 15th 2019Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).
Read More